Antitrust Antitrust

Sandoz to pay $195 million to resolve DOJ’s criminal generics investigation (correct*)

By Max Fillion
  • 02 Mar 2020 18:10
  • 03 Mar 2020 12:19
Drugmaker Sandoz will pay $195 million as part of a deferred prosecution agreement it struck with the US Department of Justice to resolve criminal charges for its role in several conspiracies to drive up the price of generic drugs. A DPA was used to avoid barring Sandoz from participation in federal health

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News